"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","characteristics_ch1.3","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","description","description.1","data_processing","platform_id","contact_name","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","supplementary_file","data_row_count","disease state:ch1","individual:ch1","sample type:ch1","treatment status of liver disease:ch1"
"GSM2281142","patient 20 HCC-001","GSM2281142","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 20","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 020-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281142/suppl/GSM2281142_SH57D54_Cell4_20150929_1309_1Color_IntegratedResult.txt.gz","2565","HCC","patient 20","exosome","before IFN treatment"
"GSM2281143","patient 19 HCC-002","GSM2281143","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 19","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 019-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281143/suppl/GSM2281143_SH57D54_Cell2_20150929_1307_1Color_IntegratedResult.txt.gz","2565","HCC","patient 19","exosome","after IFN treatment"
"GSM2281144","patient 19 HCC-001","GSM2281144","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 19","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 019-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281144/suppl/GSM2281144_SH57D54_Cell1_20150929_1306_1Color_IntegratedResult.txt.gz","2565","HCC","patient 19","exosome","before IFN treatment"
"GSM2281145","patient 18 HCC-003","GSM2281145","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 18","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 018-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281145/suppl/GSM2281145_SH57D53_Cell4_20150929_1305_1Color_IntegratedResult.txt.gz","2565","HCC","patient 18","exosome","HCC"
"GSM2281146","patient 18 HCC-002","GSM2281146","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 18","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 018-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281146/suppl/GSM2281146_SH57D53_Cell3_20150929_1304_1Color_IntegratedResult.txt.gz","2565","HCC","patient 18","exosome","after IFN treatment"
"GSM2281147","patient 18 HCC-001","GSM2281147","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 18","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 018-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281147/suppl/GSM2281147_SH57D53_Cell2_20150929_1303_1Color_IntegratedResult.txt.gz","2565","HCC","patient 18","exosome","before IFN treatment"
"GSM2281148","patient 17 HCC-003","GSM2281148","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 17","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 017-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281148/suppl/GSM2281148_SH57D53_Cell1_20150929_1302_1Color_IntegratedResult.txt.gz","2565","HCC","patient 17","exosome","HCC"
"GSM2281149","patient 17 HCC-002","GSM2281149","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 17","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 017-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281149/suppl/GSM2281149_SH57D52_Cell4_20150929_1301_1Color_IntegratedResult.txt.gz","2565","HCC","patient 17","exosome","after IFN treatment"
"GSM2281150","patient 17 HCC-001","GSM2281150","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 17","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 017-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281150/suppl/GSM2281150_SH57D52_Cell3_20150929_1300_1Color_IntegratedResult.txt.gz","2565","HCC","patient 17","exosome","before IFN treatment"
"GSM2281151","patient 16 HCC-003","GSM2281151","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 16","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 016-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281151/suppl/GSM2281151_SH57D52_Cell2_20150929_1259_1Color_IntegratedResult.txt.gz","2565","HCC","patient 16","exosome","HCC"
"GSM2281152","patient 16 HCC-002","GSM2281152","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 16","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 016-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281152/suppl/GSM2281152_SH57D52_Cell1_20150929_1258_1Color_IntegratedResult.txt.gz","2565","HCC","patient 16","exosome","after IFN treatment"
"GSM2281153","patient 16 HCC-001","GSM2281153","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 16","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 016-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281153/suppl/GSM2281153_SH57D51_Cell4_20150929_1257_1Color_IntegratedResult.txt.gz","2565","HCC","patient 16","exosome","before IFN treatment"
"GSM2281154","patient 15 HCC-003","GSM2281154","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 15","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 015-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281154/suppl/GSM2281154_SH57D51_Cell3_20150929_1256_1Color_IntegratedResult.txt.gz","2565","HCC","patient 15","exosome","HCC"
"GSM2281155","patient 15 HCC-002","GSM2281155","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 15","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 015-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281155/suppl/GSM2281155_SH57D51_Cell2_20150929_1255_1Color_IntegratedResult.txt.gz","2565","HCC","patient 15","exosome","after IFN treatment"
"GSM2281156","patient 15 HCC-001","GSM2281156","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 15","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 015-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281156/suppl/GSM2281156_SH57D51_Cell1_20150929_1254_1Color_IntegratedResult.txt.gz","2565","HCC","patient 15","exosome","before IFN treatment"
"GSM2281157","patient 14 HCC-003","GSM2281157","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 14","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 014-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281157/suppl/GSM2281157_SH57D50_Cell4_20150929_1253_1Color_IntegratedResult.txt.gz","2565","HCC","patient 14","exosome","HCC"
"GSM2281158","patient 14 HCC-002","GSM2281158","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 14","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 014-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281158/suppl/GSM2281158_SH57D50_Cell3_20150929_1252_1Color_IntegratedResult.txt.gz","2565","HCC","patient 14","exosome","after IFN treatment"
"GSM2281159","patient 14 HCC-001","GSM2281159","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 14","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 014-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281159/suppl/GSM2281159_SH57D50_Cell2_20150929_1251_1Color_IntegratedResult.txt.gz","2565","HCC","patient 14","exosome","before IFN treatment"
"GSM2281160","patient 13 HCC-003","GSM2281160","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 13","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 013-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281160/suppl/GSM2281160_SH57D50_Cell1_20150929_1250_1Color_IntegratedResult.txt.gz","2565","HCC","patient 13","exosome","HCC"
"GSM2281161","patient 13 HCC-002","GSM2281161","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 13","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 013-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281161/suppl/GSM2281161_SH57D49_Cell4_20150929_1249_1Color_IntegratedResult.txt.gz","2565","HCC","patient 13","exosome","after IFN treatment"
"GSM2281162","patient 13 HCC-001","GSM2281162","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 13","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 013-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281162/suppl/GSM2281162_SH57D49_Cell3_20150929_1248_1Color_IntegratedResult.txt.gz","2565","HCC","patient 13","exosome","before IFN treatment"
"GSM2281163","patient 12 HCC-003","GSM2281163","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 12","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 012-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281163/suppl/GSM2281163_SH57D49_Cell2_20150929_1247_1Color_IntegratedResult.txt.gz","2565","HCC","patient 12","exosome","HCC"
"GSM2281164","patient 12 HCC-002","GSM2281164","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 12","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 012-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281164/suppl/GSM2281164_SH57D49_Cell1_20150929_1246_1Color_IntegratedResult.txt.gz","2565","HCC","patient 12","exosome","after IFN treatment"
"GSM2281165","patient 12 HCC-001","GSM2281165","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 12","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 012-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281165/suppl/GSM2281165_SH57D46_Cell4_20150929_1245_1Color_IntegratedResult.txt.gz","2565","HCC","patient 12","exosome","before IFN treatment"
"GSM2281166","patient 11 HCC-003","GSM2281166","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 11","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 011-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281166/suppl/GSM2281166_SH57D46_Cell3_20150929_1244_1Color_IntegratedResult.txt.gz","2565","HCC","patient 11","exosome","HCC"
"GSM2281167","patient 11 HCC-002","GSM2281167","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 11","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 011-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281167/suppl/GSM2281167_SH57D46_Cell2_20150929_1243_1Color_IntegratedResult.txt.gz","2565","HCC","patient 11","exosome","after IFN treatment"
"GSM2281168","patient 11 HCC-001","GSM2281168","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 11","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 011-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281168/suppl/GSM2281168_SH57D46_Cell1_20150929_1242_1Color_IntegratedResult.txt.gz","2565","HCC","patient 11","exosome","before IFN treatment"
"GSM2281169","patient 22 HCC-003","GSM2281169","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 22","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 022-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281169/suppl/GSM2281169_SH57D56_Cell4_20150929_1317_1Color_IntegratedResult.txt.gz","2565","HCC","patient 22","exosome","HCC"
"GSM2281170","patient 22 HCC-002","GSM2281170","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 22","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 022-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281170/suppl/GSM2281170_SH57D56_Cell3_20150929_1316_1Color_IntegratedResult.txt.gz","2565","HCC","patient 22","exosome","after IFN treatment"
"GSM2281171","patient 22 HCC-001","GSM2281171","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 22","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 022-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281171/suppl/GSM2281171_SH57D56_Cell2_20150929_1315_1Color_IntegratedResult.txt.gz","2565","HCC","patient 22","exosome","before IFN treatment"
"GSM2281172","patient 21 HCC-003","GSM2281172","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 21","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 021-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281172/suppl/GSM2281172_SH57D56_Cell1_20150929_1314_1Color_IntegratedResult.txt.gz","2565","HCC","patient 21","exosome","HCC"
"GSM2281173","patient 21 HCC-002","GSM2281173","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 21","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 021-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281173/suppl/GSM2281173_SH57D55_Cell4_20150929_1313_1Color_IntegratedResult.txt.gz","2565","HCC","patient 21","exosome","after IFN treatment"
"GSM2281174","patient 21 HCC-001","GSM2281174","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 21","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 021-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281174/suppl/GSM2281174_SH57D55_Cell3_20150929_1312_1Color_IntegratedResult.txt.gz","2565","HCC","patient 21","exosome","before IFN treatment"
"GSM2281175","patient 20 HCC-003","GSM2281175","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 20","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 020-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281175/suppl/GSM2281175_SH57D55_Cell2_20150929_1311_1Color_IntegratedResult.txt.gz","2565","HCC","patient 20","exosome","HCC"
"GSM2281176","patient 20 HCC-002","GSM2281176","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 20","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 020-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281176/suppl/GSM2281176_SH57D55_Cell1_20150929_1310_1Color_IntegratedResult.txt.gz","2565","HCC","patient 20","exosome","after IFN treatment"
"GSM2281177","patient 19 HCC-003","GSM2281177","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 19","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC 019-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281177/suppl/GSM2281177_SH58Z23_Cell4_20151105_1815_1Color_IntegratedResult.txt.gz","2565","HCC","patient 19","exosome","HCC"
"GSM2281178","patient 1 HCC-001","GSM2281178","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 1","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC001-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281178/suppl/GSM2281178_SH54613_Cell1_20150626_1448_1Color_IntegratedResult.txt.gz","2565","HCC","patient 1","exosome","before IFN treatment"
"GSM2281179","patient 1 HCC-002","GSM2281179","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 1","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC001-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281179/suppl/GSM2281179_SH54613_Cell2_20150626_1449_1Color_IntegratedResult.txt.gz","2565","HCC","patient 1","exosome","after IFN treatment"
"GSM2281180","patient 2 HCC-001","GSM2281180","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 2","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC002-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281180/suppl/GSM2281180_SH54613_Cell3_20150626_1450_1Color_IntegratedResult.txt.gz","2565","HCC","patient 2","exosome","HCC"
"GSM2281181","patient 2 HCC-002","GSM2281181","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 2","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC002-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281181/suppl/GSM2281181_SH54613_Cell4_20150626_1451_1Color_IntegratedResult.txt.gz","2565","HCC","patient 2","exosome","after IFN treatment"
"GSM2281182","patient 2 HCC-003","GSM2281182","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 2","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC002-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281182/suppl/GSM2281182_SH54614_Cell1_20150626_1452_1Color_IntegratedResult.txt.gz","2565","HCC","patient 2","exosome","HCC"
"GSM2281183","patient 3 HCC-001","GSM2281183","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 3","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC003-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281183/suppl/GSM2281183_SH54614_Cell2_20150626_1453_1Color_IntegratedResult.txt.gz","2565","HCC","patient 3","exosome","before IFN treatment"
"GSM2281184","patient 3 HCC-002","GSM2281184","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 3","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC003-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281184/suppl/GSM2281184_SH54614_Cell3_20150626_1454_1Color_IntegratedResult.txt.gz","2565","HCC","patient 3","exosome","after IFN treatment"
"GSM2281185","patient 3 HCC-003","GSM2281185","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 3","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC003-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281185/suppl/GSM2281185_SH54614_Cell4_20150626_1455_1Color_IntegratedResult.txt.gz","2565","HCC","patient 3","exosome","HCC"
"GSM2281186","patient 4 HCC-001","GSM2281186","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 4","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC004-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281186/suppl/GSM2281186_SH54615_Cell1_20150626_1456_1Color_IntegratedResult.txt.gz","2565","HCC","patient 4","exosome","before IFN treatment"
"GSM2281187","patient 4 HCC-002","GSM2281187","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 4","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC004-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281187/suppl/GSM2281187_SH54615_Cell2_20150626_1457_1Color_IntegratedResult.txt.gz","2565","HCC","patient 4","exosome","after IFN treatment"
"GSM2281188","patient 4 HCC-003","GSM2281188","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 4","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC004-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281188/suppl/GSM2281188_SH54615_Cell3_20150626_1458_1Color_IntegratedResult.txt.gz","2565","HCC","patient 4","exosome","HCC"
"GSM2281189","patient 5 HCC-001","GSM2281189","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 5","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC005-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281189/suppl/GSM2281189_SH54615_Cell4_20150626_1459_1Color_IntegratedResult.txt.gz","2565","HCC","patient 5","exosome","before IFN treatment"
"GSM2281190","patient 5 HCC-002","GSM2281190","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 5","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC005-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281190/suppl/GSM2281190_SH54616_Cell1_20150626_1500_1Color_IntegratedResult.txt.gz","2565","HCC","patient 5","exosome","after IFN treatment"
"GSM2281191","patient 5 HCC-003","GSM2281191","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 5","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC005-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281191/suppl/GSM2281191_SH54616_Cell2_20150626_1501_1Color_IntegratedResult.txt.gz","2565","HCC","patient 5","exosome","HCC"
"GSM2281192","patient 6 HCC-001","GSM2281192","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 6","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC006-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281192/suppl/GSM2281192_SH54616_Cell3_20150626_1502_1Color_IntegratedResult.txt.gz","2565","HCC","patient 6","exosome","before IFN treatment"
"GSM2281193","patient 6 HCC-002","GSM2281193","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 6","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC006-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281193/suppl/GSM2281193_SH54616_Cell4_20150626_1503_1Color_IntegratedResult.txt.gz","2565","HCC","patient 6","exosome","after IFN treatment"
"GSM2281194","patient 6 HCC-003","GSM2281194","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 6","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC006-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281194/suppl/GSM2281194_SH54617_Cell1_20150626_1504_1Color_IntegratedResult.txt.gz","2565","HCC","patient 6","exosome","HCC"
"GSM2281195","patient 7 HCC-001","GSM2281195","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 7","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC007-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281195/suppl/GSM2281195_SH54617_Cell2_20150626_1505_1Color_IntegratedResult.txt.gz","2565","HCC","patient 7","exosome","before IFN treatment"
"GSM2281196","patient 7 HCC-002","GSM2281196","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 7","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC007-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281196/suppl/GSM2281196_SH54617_Cell3_20150626_1506_1Color_IntegratedResult.txt.gz","2565","HCC","patient 7","exosome","after IFN treatment"
"GSM2281197","patient 7 HCC-003","GSM2281197","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 7","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC007-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281197/suppl/GSM2281197_SH54617_Cell4_20150626_1507_1Color_IntegratedResult.txt.gz","2565","HCC","patient 7","exosome","HCC"
"GSM2281198","patient 8 HCC-001","GSM2281198","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 8","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC008-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281198/suppl/GSM2281198_SH54618_Cell1_20150626_1508_1Color_IntegratedResult.txt.gz","2565","HCC","patient 8","exosome","before IFN treatment"
"GSM2281199","patient 8 HCC-002","GSM2281199","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 8","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC008-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281199/suppl/GSM2281199_SH54618_Cell2_20150626_1509_1Color_IntegratedResult.txt.gz","2565","HCC","patient 8","exosome","after IFN treatment"
"GSM2281200","patient 8 HCC-003","GSM2281200","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 8","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC008-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281200/suppl/GSM2281200_SH54618_Cell3_20150626_1510_1Color_IntegratedResult.txt.gz","2565","HCC","patient 8","exosome","HCC"
"GSM2281201","patient 9 HCC-001","GSM2281201","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 9","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC009-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281201/suppl/GSM2281201_SH54618_Cell4_20150626_1511_1Color_IntegratedResult.txt.gz","2565","HCC","patient 9","exosome","before IFN treatment"
"GSM2281202","patient 9 HCC-002","GSM2281202","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 9","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC009-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281202/suppl/GSM2281202_SH54619_Cell1_20150626_1512_1Color_IntegratedResult.txt.gz","2565","HCC","patient 9","exosome","after IFN treatment"
"GSM2281203","patient 9 HCC-003","GSM2281203","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 9","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC009-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281203/suppl/GSM2281203_SH54619_Cell2_20150626_1513_1Color_IntegratedResult.txt.gz","2565","HCC","patient 9","exosome","HCC"
"GSM2281204","patient 10 HCC-001","GSM2281204","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 10","disease state: HCC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC010-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281204/suppl/GSM2281204_SH54619_Cell3_20150626_1514_1Color_IntegratedResult.txt.gz","2565","HCC","patient 10","exosome","before IFN treatment"
"GSM2281205","patient 10 HCC-002","GSM2281205","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 10","disease state: HCC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC010-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281205/suppl/GSM2281205_SH54619_Cell4_20150626_1515_1Color_IntegratedResult.txt.gz","2565","HCC","patient 10","exosome","after IFN treatment"
"GSM2281206","patient 10 HCC-003","GSM2281206","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 10","disease state: HCC","treatment status of liver disease: HCC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","hepatocellular carcicoma (HCC)","SVR-HCC010-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281206/suppl/GSM2281206_SH54620_Cell1_20150626_1516_1Color_IntegratedResult.txt.gz","2565","HCC","patient 10","exosome","HCC"
"GSM2281207","patient 23 CHC-001","GSM2281207","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 23","disease state: CHC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC001-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281207/suppl/GSM2281207_SH54620_Cell2_20150626_1517_1Color_IntegratedResult.txt.gz","2565","CHC","patient 23","exosome","before IFN treatment"
"GSM2281208","patient 23 CHC-002","GSM2281208","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 23","disease state: CHC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC001-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281208/suppl/GSM2281208_SH54620_Cell3_20150626_1518_1Color_IntegratedResult.txt.gz","2565","CHC","patient 23","exosome","after IFN treatment"
"GSM2281209","patient 23 CHC-003","GSM2281209","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 23","disease state: CHC","treatment status of liver disease: CHC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC001-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281209/suppl/GSM2281209_SH54620_Cell4_20150626_1519_1Color_IntegratedResult.txt.gz","2565","CHC","patient 23","exosome","CHC"
"GSM2281210","patient 24 CHC-001","GSM2281210","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 24","disease state: CHC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC002-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281210/suppl/GSM2281210_SH54621_Cell1_20150626_1520_1Color_IntegratedResult.txt.gz","2565","CHC","patient 24","exosome","before IFN treatment"
"GSM2281211","patient 24 CHC-002","GSM2281211","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 24","disease state: CHC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC002-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281211/suppl/GSM2281211_SH54621_Cell2_20150626_1521_1Color_IntegratedResult.txt.gz","2565","CHC","patient 24","exosome","after IFN treatment"
"GSM2281212","patient 24 CHC-003","GSM2281212","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 24","disease state: CHC","treatment status of liver disease: CHC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC002-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281212/suppl/GSM2281212_SH54621_Cell3_20150626_1522_1Color_IntegratedResult.txt.gz","2565","CHC","patient 24","exosome","CHC"
"GSM2281213","patient 25 CHC-001","GSM2281213","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 25","disease state: CHC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC003-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281213/suppl/GSM2281213_SH54621_Cell4_20150626_1523_1Color_IntegratedResult.txt.gz","2565","CHC","patient 25","exosome","before IFN treatment"
"GSM2281214","patient 25 CHC-002","GSM2281214","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 25","disease state: CHC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC003-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281214/suppl/GSM2281214_SH54622_Cell1_20150626_1524_1Color_IntegratedResult.txt.gz","2565","CHC","patient 25","exosome","after IFN treatment"
"GSM2281215","patient 25 CHC-003","GSM2281215","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 25","disease state: CHC","treatment status of liver disease: CHC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC003-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281215/suppl/GSM2281215_SH54622_Cell2_20150626_1525_1Color_IntegratedResult.txt.gz","2565","CHC","patient 25","exosome","CHC"
"GSM2281216","patient 26 CHC-001","GSM2281216","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 26","disease state: CHC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC004-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281216/suppl/GSM2281216_SH54622_Cell3_20150626_1526_1Color_IntegratedResult.txt.gz","2565","CHC","patient 26","exosome","before IFN treatment"
"GSM2281217","patient 26 CHC-002","GSM2281217","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 26","disease state: CHC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC004-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281217/suppl/GSM2281217_SH54622_Cell4_20150626_1527_1Color_IntegratedResult.txt.gz","2565","CHC","patient 26","exosome","after IFN treatment"
"GSM2281218","patient 26 CHC-003","GSM2281218","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 26","disease state: CHC","treatment status of liver disease: CHC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC004-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281218/suppl/GSM2281218_SH54623_Cell1_20150630_1312_1Color_IntegratedResult.txt.gz","2565","CHC","patient 26","exosome","CHC"
"GSM2281219","patient 27 CHC-001","GSM2281219","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 27","disease state: CHC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC005-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281219/suppl/GSM2281219_SH54623_Cell2_20150630_1313_1Color_IntegratedResult.txt.gz","2565","CHC","patient 27","exosome","before IFN treatment"
"GSM2281220","patient 27 CHC-002","GSM2281220","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 27","disease state: CHC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC005-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281220/suppl/GSM2281220_SH54623_Cell3_20150630_1314_1Color_IntegratedResult.txt.gz","2565","CHC","patient 27","exosome","after IFN treatment"
"GSM2281221","patient 27 CHC-003","GSM2281221","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 27","disease state: CHC","treatment status of liver disease: CHC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC005-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281221/suppl/GSM2281221_SH54623_Cell4_20150630_1315_1Color_IntegratedResult.txt.gz","2565","CHC","patient 27","exosome","CHC"
"GSM2281222","patient 28 CHC-001","GSM2281222","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 28","disease state: CHC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC006-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281222/suppl/GSM2281222_SH54625_Cell1_20150630_1316_1Color_IntegratedResult.txt.gz","2565","CHC","patient 28","exosome","before IFN treatment"
"GSM2281223","patient 28 CHC-002","GSM2281223","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 28","disease state: CHC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC006-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281223/suppl/GSM2281223_SH54625_Cell2_20150630_1317_1Color_IntegratedResult.txt.gz","2565","CHC","patient 28","exosome","after IFN treatment"
"GSM2281224","patient 28 CHC-003","GSM2281224","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 28","disease state: CHC","treatment status of liver disease: CHC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC006-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281224/suppl/GSM2281224_SH54625_Cell3_20150630_1318_1Color_IntegratedResult.txt.gz","2565","CHC","patient 28","exosome","CHC"
"GSM2281225","patient 29 CHC-001","GSM2281225","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 29","disease state: CHC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC007-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281225/suppl/GSM2281225_SH54625_Cell4_20150630_1319_1Color_IntegratedResult.txt.gz","2565","CHC","patient 29","exosome","before IFN treatment"
"GSM2281226","patient 29 CHC-002","GSM2281226","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 29","disease state: CHC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC007-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281226/suppl/GSM2281226_SH54626_Cell1_20150630_1320_1Color_IntegratedResult.txt.gz","2565","CHC","patient 29","exosome","after IFN treatment"
"GSM2281227","patient 29 CHC-003","GSM2281227","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 29","disease state: CHC","treatment status of liver disease: CHC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC007-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281227/suppl/GSM2281227_SH54626_Cell2_20150630_1321_1Color_IntegratedResult.txt.gz","2565","CHC","patient 29","exosome","CHC"
"GSM2281228","patient 30 CHC-001","GSM2281228","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 30","disease state: CHC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC008-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281228/suppl/GSM2281228_SH54626_Cell3_20150630_1322_1Color_IntegratedResult.txt.gz","2565","CHC","patient 30","exosome","before IFN treatment"
"GSM2281229","patient 30 CHC-002","GSM2281229","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 30","disease state: CHC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC008-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281229/suppl/GSM2281229_SH54626_Cell4_20150630_1323_1Color_IntegratedResult.txt.gz","2565","CHC","patient 30","exosome","after IFN treatment"
"GSM2281230","patient 30 CHC-003","GSM2281230","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 30","disease state: CHC","treatment status of liver disease: CHC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC008-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281230/suppl/GSM2281230_SH54627_Cell1_20150630_1324_1Color_IntegratedResult.txt.gz","2565","CHC","patient 30","exosome","CHC"
"GSM2281231","patient 31 CHC-001","GSM2281231","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 31","disease state: CHC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC009-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281231/suppl/GSM2281231_SH54627_Cell2_20150630_1325_1Color_IntegratedResult.txt.gz","2565","CHC","patient 31","exosome","before IFN treatment"
"GSM2281232","patient 31 CHC-002","GSM2281232","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 31","disease state: CHC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC009-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281232/suppl/GSM2281232_SH54627_Cell3_20150630_1326_1Color_IntegratedResult.txt.gz","2565","CHC","patient 31","exosome","after IFN treatment"
"GSM2281233","patient 31 CHC-003","GSM2281233","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 31","disease state: CHC","treatment status of liver disease: CHC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC009-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281233/suppl/GSM2281233_SH54627_Cell4_20150630_1327_1Color_IntegratedResult.txt.gz","2565","CHC","patient 31","exosome","CHC"
"GSM2281234","patient 32 CHC-001","GSM2281234","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 32","disease state: CHC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC010-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281234/suppl/GSM2281234_SH54628_Cell1_20150630_1328_1Color_IntegratedResult.txt.gz","2565","CHC","patient 32","exosome","before IFN treatment"
"GSM2281235","patient 32 CHC-002","GSM2281235","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 32","disease state: CHC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC010-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281235/suppl/GSM2281235_SH54628_Cell2_20150630_1329_1Color_IntegratedResult.txt.gz","2565","CHC","patient 32","exosome","after IFN treatment"
"GSM2281236","patient 32 CHC-003","GSM2281236","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 32","disease state: CHC","treatment status of liver disease: CHC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC010-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281236/suppl/GSM2281236_SH54628_Cell3_20150630_1330_1Color_IntegratedResult.txt.gz","2565","CHC","patient 32","exosome","CHC"
"GSM2281237","patient 33 CHC-001","GSM2281237","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 33","disease state: CHC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC011-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281237/suppl/GSM2281237_SH54628_Cell4_20150630_1331_1Color_IntegratedResult.txt.gz","2565","CHC","patient 33","exosome","before IFN treatment"
"GSM2281238","patient 33 CHC-002","GSM2281238","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 33","disease state: CHC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC011-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281238/suppl/GSM2281238_SH54629_Cell1_20150630_1332_1Color_IntegratedResult.txt.gz","2565","CHC","patient 33","exosome","after IFN treatment"
"GSM2281239","patient 33 CHC-003","GSM2281239","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 33","disease state: CHC","treatment status of liver disease: CHC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC011-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281239/suppl/GSM2281239_SH54629_Cell2_20150630_1333_1Color_IntegratedResult.txt.gz","2565","CHC","patient 33","exosome","CHC"
"GSM2281240","patient 34 CHC-001","GSM2281240","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 34","disease state: CHC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC012-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281240/suppl/GSM2281240_SH54629_Cell3_20150630_1334_1Color_IntegratedResult.txt.gz","2565","CHC","patient 34","exosome","before IFN treatment"
"GSM2281241","patient 34 CHC-002","GSM2281241","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 34","disease state: CHC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC012-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281241/suppl/GSM2281241_SH54629_Cell4_20150630_1335_1Color_IntegratedResult.txt.gz","2565","CHC","patient 34","exosome","after IFN treatment"
"GSM2281242","patient 34 CHC-003","GSM2281242","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 34","disease state: CHC","treatment status of liver disease: CHC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC012-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281242/suppl/GSM2281242_SH54631_Cell1_20150630_1336_1Color_IntegratedResult.txt.gz","2565","CHC","patient 34","exosome","CHC"
"GSM2281243","patient 35 CHC-001","GSM2281243","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 35","disease state: CHC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC013-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281243/suppl/GSM2281243_SH54631_Cell2_20150630_1337_1Color_IntegratedResult.txt.gz","2565","CHC","patient 35","exosome","before IFN treatment"
"GSM2281244","patient 35 CHC-002","GSM2281244","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 35","disease state: CHC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC013-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281244/suppl/GSM2281244_SH54631_Cell3_20150630_1338_1Color_IntegratedResult.txt.gz","2565","CHC","patient 35","exosome","after IFN treatment"
"GSM2281245","patient 35 CHC-003","GSM2281245","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 35","disease state: CHC","treatment status of liver disease: CHC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC013-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281245/suppl/GSM2281245_SH54631_Cell4_20150630_1339_1Color_IntegratedResult.txt.gz","2565","CHC","patient 35","exosome","CHC"
"GSM2281246","patient 36 CHC-001","GSM2281246","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 36","disease state: CHC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC014-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281246/suppl/GSM2281246_SH54633_Cell1_20150630_1340_1Color_IntegratedResult.txt.gz","2565","CHC","patient 36","exosome","before IFN treatment"
"GSM2281247","patient 36 CHC-002","GSM2281247","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 36","disease state: CHC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC014-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281247/suppl/GSM2281247_SH54633_Cell2_20150630_1341_1Color_IntegratedResult.txt.gz","2565","CHC","patient 36","exosome","after IFN treatment"
"GSM2281248","patient 36 CHC-003","GSM2281248","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 36","disease state: CHC","treatment status of liver disease: CHC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC014-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281248/suppl/GSM2281248_SH54633_Cell3_20150630_1342_1Color_IntegratedResult.txt.gz","2565","CHC","patient 36","exosome","CHC"
"GSM2281249","patient 37 CHC-001","GSM2281249","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 37","disease state: CHC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC015-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281249/suppl/GSM2281249_SH54633_Cell4_20150630_1343_1Color_IntegratedResult.txt.gz","2565","CHC","patient 37","exosome","before IFN treatment"
"GSM2281250","patient 37 CHC-002","GSM2281250","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 37","disease state: CHC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC015-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281250/suppl/GSM2281250_SH54635_Cell1_20150630_1344_1Color_IntegratedResult.txt.gz","2565","CHC","patient 37","exosome","after IFN treatment"
"GSM2281251","patient 37 CHC-003","GSM2281251","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 37","disease state: CHC","treatment status of liver disease: CHC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC015-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281251/suppl/GSM2281251_SH54635_Cell2_20150630_1345_1Color_IntegratedResult.txt.gz","2565","CHC","patient 37","exosome","CHC"
"GSM2281252","patient 38 CHC-001","GSM2281252","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 38","disease state: CHC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC016-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281252/suppl/GSM2281252_SH54635_Cell3_20150630_1346_1Color_IntegratedResult.txt.gz","2565","CHC","patient 38","exosome","before IFN treatment"
"GSM2281253","patient 38 CHC-002","GSM2281253","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 38","disease state: CHC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC016-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281253/suppl/GSM2281253_SH54635_Cell4_20150630_1347_1Color_IntegratedResult.txt.gz","2565","CHC","patient 38","exosome","after IFN treatment"
"GSM2281254","patient 38 CHC-003","GSM2281254","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 38","disease state: CHC","treatment status of liver disease: CHC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC016-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281254/suppl/GSM2281254_SH54638_Cell1_20150630_1348_1Color_IntegratedResult.txt.gz","2565","CHC","patient 38","exosome","CHC"
"GSM2281255","patient 39 CHC-001","GSM2281255","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 39","disease state: CHC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC017-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281255/suppl/GSM2281255_SH54638_Cell2_20150630_1349_1Color_IntegratedResult.txt.gz","2565","CHC","patient 39","exosome","before IFN treatment"
"GSM2281256","patient 39 CHC-002","GSM2281256","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 39","disease state: CHC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC017-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281256/suppl/GSM2281256_SH54638_Cell3_20150630_1350_1Color_IntegratedResult.txt.gz","2565","CHC","patient 39","exosome","after IFN treatment"
"GSM2281257","patient 39 CHC-003","GSM2281257","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 39","disease state: CHC","treatment status of liver disease: CHC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC017-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281257/suppl/GSM2281257_SH54638_Cell4_20150630_1351_1Color_IntegratedResult.txt.gz","2565","CHC","patient 39","exosome","CHC"
"GSM2281258","patient 40 CHC-001","GSM2281258","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 40","disease state: CHC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC018-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281258/suppl/GSM2281258_SH54660_Cell3_20150701_1549_1Color_IntegratedResult.txt.gz","2565","CHC","patient 40","exosome","before IFN treatment"
"GSM2281259","patient 40 CHC-002","GSM2281259","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 40","disease state: CHC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC018-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281259/suppl/GSM2281259_SH54660_Cell4_20150701_1550_1Color_IntegratedResult.txt.gz","2565","CHC","patient 40","exosome","after IFN treatment"
"GSM2281260","patient 40 CHC-003","GSM2281260","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 40","disease state: CHC","treatment status of liver disease: CHC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC018-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281260/suppl/GSM2281260_SH54661_Cell1_20150701_1457_1Color_IntegratedResult.txt.gz","2565","CHC","patient 40","exosome","CHC"
"GSM2281261","patient 41 CHC-001","GSM2281261","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 41","disease state: CHC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC019-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281261/suppl/GSM2281261_SH54661_Cell2_20150701_1458_1Color_IntegratedResult.txt.gz","2565","CHC","patient 41","exosome","before IFN treatment"
"GSM2281262","patient 41 CHC-002","GSM2281262","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 41","disease state: CHC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC019-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281262/suppl/GSM2281262_SH54661_Cell3_20150701_1459_1Color_IntegratedResult.txt.gz","2565","CHC","patient 41","exosome","after IFN treatment"
"GSM2281263","patient 41 CHC-003","GSM2281263","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 41","disease state: CHC","treatment status of liver disease: CHC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC019-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281263/suppl/GSM2281263_SH54661_Cell4_20150701_1500_1Color_IntegratedResult.txt.gz","2565","CHC","patient 41","exosome","CHC"
"GSM2281264","patient 42 CHC-001","GSM2281264","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 42","disease state: CHC","treatment status of liver disease: before IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC020-1","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281264/suppl/GSM2281264_SH54801_Cell1_20150701_1501_1Color_IntegratedResult.txt.gz","2565","CHC","patient 42","exosome","before IFN treatment"
"GSM2281265","patient 42 CHC-002","GSM2281265","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 42","disease state: CHC","treatment status of liver disease: after IFN treatment","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC020-2","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281265/suppl/GSM2281265_SH54801_Cell2_20150701_1502_1Color_IntegratedResult.txt.gz","2565","CHC","patient 42","exosome","after IFN treatment"
"GSM2281266","patient 42 CHC-003","GSM2281266","Public on Dec 31 2016","Aug 16 2016","Dec 31 2016","RNA","1","exosome","Homo sapiens","individual: patient 42","disease state: CHC","treatment status of liver disease: CHC","sample type: exosome","total RNA","RNA samples were extracted from serum using 3D-Gene RNA extraction reagent from liquid sampld (Toray Industries Inc., Tokyo, Japan)..","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","chronic hepatitis C (CHC)","HCV-CHC020-3","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoshi,,Kondo","Toray Industries,Inc.","10-1 tebiro 6-chome","Kamakura","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2281nnn/GSM2281266/suppl/GSM2281266_SH54801_Cell3_20150701_1503_1Color_IntegratedResult.txt.gz","2565","CHC","patient 42","exosome","CHC"
